Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy – United States Forecast to 2027 – Cumulative Impact of COVID-19 –

Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy – United States Forecast to 2027 – Cumulative Impact of COVID-19 –

Gene Therapy Market Research Report 2022: Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy – United States Forecast to 2027 – Cumulative Impact of COVID-19 –

DUBLIN–(BUSINESS WIRE)–The “Gene Therapy Market Research Report by Type (Antigen Gene Therapy, Cancer Gene Therapy, and Cytokine Gene Therapy), Vector Type, Application, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to’s offering.

The United States Gene Therapy Market size was estimated at USD 575.53 million in 2021, USD 740.95 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 24.70% to reach USD 2,164.11 million by 2027.

In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward.

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.

Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report answers questions such as:

1. What is the market size and forecast of the United States Gene Therapy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the United States Gene Therapy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Gene Therapy Market?

4. What is the competitive strategic window for opportunities in the United States Gene Therapy Market?

5. What are the technology trends and regulatory frameworks in the United States Gene Therapy Market?

6. What is the market share of the leading vendors in the United States Gene Therapy Market?

7. What modes and strategic moves are considered suitable for entering the United States Gene Therapy Market?

Company Usability Profiles:

  • Abeona Therapeutics, Inc.,
  • Achieve Life Sciences, Inc.
  • Adaptimmune
  • AGTC
  • Akcea Therapeutics
  • Alnylam Pharmaceuticals, Inc.
  • Amgen, Inc.
  • AnGes, Inc.
  • Audentes Therapeutics
  • Biogen
  • Bluebird bio, Inc.
  • Dynavax Technologies
  • Editas Medicine
  • Gilead Sciences, Inc.
  • Human Stem Cells Institute
  • Jazz Pharmaceuticals, Inc.
  • Merck & Co., Inc
  • MolMed S.p.A.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Spark Therapeutics, Inc.

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Limitations

1.7. Assumptions

1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective

2.2. Determine: Research Design

2.3. Prepare: Research Instrument

2.4. Collect: Data Source

2.5. Analyze: Data Interpretation

2.6. Formulate: Data Verification

2.7. Publish: Research Report

2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.2. Restraints

5.1.3. Opportunities

5.1.4. Challenges

5.2. Cumulative Impact of COVID-19

6. Gene Therapy Market, by Type

6.1. Introduction

6.2. Antigen Gene Therapy

6.3. Cancer Gene Therapy

6.4. Cytokine Gene Therapy

6.5. Suicide Gene Therapy

6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

7.1. Introduction

7.2. Non-viral Vectors

7.3. Viral Vectors

8. Gene Therapy Market, by Application

8.1. Introduction

8.2. Cardiovascular Diseases

8.3. Genetic Diseases

8.4. Infectious Diseases

8.5. Neurological Diseases

8.6. Oncological Disorders

9. California Gene Therapy Market

10. Florida Gene Therapy Market

11. Illinois Gene Therapy Market

12. New York Gene Therapy Market

13. Ohio Gene Therapy Market

14. Pennsylvania Gene Therapy Market

15. Texas Gene Therapy Market

16. Competitive Landscape

16.1. FPNV Positioning Matrix

16.1.1. Quadrants

16.1.2. Business Strategy

16.1.3. Product Satisfaction

16.2. Market Ranking Analysis

16.3. Market Share Analysis, By Key Player

16.4. Competitive Scenario

16.4.1. Merger & Acquisition

16.4.2. Agreement, Collaboration, & Partnership

16.4.3. New Product Launch & Enhancement

16.4.4. Investment & Funding

16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900